CRISPR Therapeutics (CRSP) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price ...

Stock analysts at Cantor Fitzgerald issued their FY2025 earnings per share (EPS) estimates for shares of CRISPR Therapeutics ...

Bullish option flow detected in Crispr Therapeutics (CRSP) with 3,734 calls trading, 1.3x expected, and implied vol increasing almost 4 points ...

Financial disclosures released ahead of confirmation hearings for Robert F. Kennedy Jr., President Trump’s nominee to lead the health ...

Arkadios Wealth Advisors lifted its position in shares of CRISPR Therapeutics AG (NASDAQ:CRSP – Free Report) by 7.7% during the 4th quarter, according to the company in its most recent Form 13F filing ...

In this article, we are going to take a look at where CRISPR Therapeutics AG (NASDAQ:CRSP) stands against other biotech stocks with the biggest upside potential. Improving Trends for Biotech ...

Those who already own the stock may retain it for some time to see if VRTX's CF sales continue to rise and how the Casgevy ...

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) and partner CRISPR Therapeutics AG (NASDAQ:CRSP) announced that the FDA has assigned Fast Track designation to their gene ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

A live webcast of the fireside chat will be available on the "Events & Presentations" page in the Investor ZUG, Switzerland and BOSTON, Jan. 07, 2025 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: ...

So, here are two companies that I think could be takeover targets in 2025. CRISPR Therapeutics (NASDAQ:CRSP) could be an attractive takeover target due to its low valuation and strong balance sheet.